Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (57)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Whyte, I.M.
Right arrow Articles by Buckley, N.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whyte, I.M.
Right arrow Articles by Buckley, N.A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2003; 96: 369-374
© 2003 Association of Physicians

Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants

I.M. Whyte1,2,, A.H. Dawson1,2 and N.A. Buckley3

From the 1 School of Population Health Sciences, Faculty of Medicine and Health Sciences, University of Newcastle, Newcastle, NSW, 2 Department of Clinical Toxicology & Pharmacology, Newcastle Mater Misericordiae Hospital, NSW, and 3 The Canberra Hospital, Woden, ACT, Australia

Received 27 August 2002 and in revised form 5 February 2003

Background: Selective serotonin reuptake inhibitors (SSRIs) and venlafaxine have been regarded as less toxic in overdose than tricyclic antidepressants (TCAs). Within the TCAs, dothiepin has greater toxicity. Venlafaxine may be more toxic than SSRIs.

Aim: To assess the toxicity in overdose of venlafaxine and SSRIs compared to TCAs, and of dothiepin compared to other TCAs.

Design: Cohort study of prospectively collected data from the Hunter area, NSW, Australia.

Methods: First admissions with antidepressant deliberate self-poisoning (DSP) (November 1994 to April 2000) were identified; the presence of seizures, life-threatening arrhythmias, coma, serotonin toxicity or ICU admission, and QRS duration were noted.

Results: There were 538 admissions, with no deaths. The odds ratio (OR) for seizures with dothiepin vs. other TCAs was 3.4 (95%CI 1.2–9.9). Seizures occurred in 7/51 (14%) venlafaxine overdoses; all patients with seizures consumed >=900 mg. The OR for seizures vs. TCAs was 4.4 (95%CI 1.4–13.8). Coma was less likely with venlafaxine and SSRIs. SSRIs, but not venlafaxine, were less likely to prolong the QRS to >=100 ms. ICU admission was less likely for SSRIs. Serotonin toxicity was much more common with venlafaxine and SSRIs.

Discussion: Venlafaxine and dothiepin are pro-convulsant in overdose. Venlafaxine is more likely to cause serotonin toxicity, but less likely to cause coma than TCAs. SSRIs are less likely to cause coma, require ICU admission, or prolong the QRS, but are more likely to cause serotonin toxicity. Antidepressants other than TCAs or venlafaxine should be considered in patients at risk of seizure or suicide.

Address correspondence to Associate Professor I.M. Whyte, Department of Clinical Toxicology & Pharmacology, Newcastle Mater Misericordiae Hospital, Locked Bag 7, Hunter Region Mail Centre NSW 2310, Australia. e-mail: mdimw{at}cc.newcastle.edu.au


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
G. Gartlehner, B. N. Gaynes, R. A. Hansen, P. Thieda, A. DeVeaugh-Geiss, E. E. Krebs, C. G. Moore, L. Morgan, and K. N. Lohr
Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians
Ann Intern Med, November 18, 2008; 149(10): 734 - 750.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
I. Anderson, I. Ferrier, R. Baldwin, P. Cowen, L Howard, G Lewis, K Matthews, R. McAllister-Williams, R. Peveler, J Scott, et al.
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
J Psychopharmacol, June 1, 2008; 22(4): 343 - 396.
[Abstract] [PDF]


Home page
Hum Exp ToxicolHome page
P Unverir, R Atilla, O Karcioglu, H Topacoglu, Y Demiral, and Y Tuncok
A retrospective analysis of antidepressant poisonings in the emergency department: 11-year experience
Human and Experimental Toxicology, October 1, 2006; 25(10): 605 - 612.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
D. Taylor and J R. Scott
Volte-faceon venlafaxine - reasons and reflections
J Psychopharmacol, September 1, 2006; 20(5): 597 - 601.
[PDF]


Home page
QJMHome page
G.M. Cooper, D.G. Le Couteur, D. Richardson, and N.A. Buckley
A randomized clinical trial of activated charcoal for the routine management of oral drug overdose
QJM, September 1, 2005; 98(9): 655 - 660.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
P. K. Gillman
Comment on: Serotonin syndrome due to co-administration of linezolid and venlafaxine
J. Antimicrob. Chemother., October 1, 2004; 54(4): 844 - 845.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.